Changchun Bcht Biotechnology Co(688276) the performance express was released on the evening of February 18. In 2021, the company achieved a total operating revenue of 1.202 billion yuan, a year-on-year decrease of 16.6%; The net profit attributable to the shareholders of the listed company was 244 million yuan, a year-on-year decrease of 41.77%.
Changchun Bcht Biotechnology Co(688276) said that covid-19 virus vaccination had a certain impact on the vaccination rate of other vaccine products. The promotion and vaccination of the company’s main products varicella live attenuated vaccine (hereinafter referred to as “varicella vaccine”) and freeze-dried nasal spray influenza live attenuated vaccine (hereinafter referred to as “nasal spray influenza vaccine”) have been greatly impacted. The more prominent impact is the promotion and vaccination of influenza vaccine. Influenza vaccination has a strong seasonality, and the applicable population of the company’s nasal spray influenza vaccine is 3 to 17 years old, which highly coincides with the key population of covid-19 vaccination in the same period, resulting in a great impact on the vaccine promotion in the overall influenza season.
In addition, in the past two years, vaccine products similar to the company have been approved for listing, and the market competition in the industry has become increasingly fierce. For example, in the competition of influenza vaccine products, although the company’s nasal spray influenza vaccine adopts nasal spray vaccination, which can effectively enhance the compliance of recipients, there are many influenza vaccine products in the market, and the market competition pressure of the company’s nasal spray influenza vaccine is still large. Industry competition brings more challenges to the market promotion of the company’s vaccine products, and also has a certain impact on product sales.
